ERBB2 and gastric cancer: In addition, a phase 1 trial that involves binary oncolytic adenovirus (CAdVEC) in combination with HER2-specific autologous CAR T-cells to treat advanced HER2-positive GC (NCT03740256) and a single arm phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intratumorally with approved ICIs in patients with recurrent or metastatic GC (NCT03544723) are underway.